Afatinib increases sensitivity to radiation in non-small cell lung cancer cells with acquired EGFR T790M mutation

Afatinib is a second-generation of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor and has shown a significant clinical benefit in non-small cell lung cancer (NSCLC) patients with EGFR-activating mutations. However, the potential therapeutic effects of afatinib combining with other...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Shirong, Zheng, Xiaoliang, Huang, Haixiu, Wu, Kan, Wang, Bing, Chen, Xufeng, Ma, Shenglin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467405/
https://www.ncbi.nlm.nih.gov/pubmed/25714021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467405/
https://www.ncbi.nlm.nih.gov/pubmed/25714021

Ejemplares similares